Advertisement

Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort

  • Caroline Hurault-DelarueEmail author
  • Isabelle Lacroix
  • Anne Bénard-Laribière
  • Jean-Louis Montastruc
  • Antoine Pariente
  • Christine Damase-Michel
Original Paper

Abstract

Background

Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France.

Methods

We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied.

Results

During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed.

Conclusions

Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.

Keywords

Drug utilisation study Psychotropic drugs Antidepressant drugs Pregnancy 

Notes

Funding

This study is part of the Drugs Systematized Assessment in real-liFe Environment (DRUGS-SAFE) research program funded by the French Medicines Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM). This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency. EFEMERIS database is funded by the ANSM, the Caisse Nationale d’Assurance Maladie des travailleurs salariés (CNAMTS) and the Clinical Research Hospital Program (PHRC).

Compliance with ethical standards

Conflict of interest

Caroline Hurault-Delarue, Isabelle Lacroix, Anne Bénard-Laribière, Jean-Louis Montastruc, Antoine Pariente and Christine Damase-Michel declare that they have no conflict of interest with the Pharmaceutical Industry.

Ethics statement

The EFEMERIS database was approved by the French Data Protection Agency (Commission Nationale de l’Informatique et des Libertés, CNIL) on 7 April 2005 (authorisation number 05-1140). Women were informed of the study and could refuse to participate. In accordance with French regulations, ethics committee approval was not required for this observational study conducted on anonymous medico-administrative data.

Supplementary material

406_2018_906_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 KB)

References

  1. 1.
    Bennett HA, Einarson A, Taddio A et al (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709.  https://doi.org/10.1097/01.AOG.0000116689.75396.5f CrossRefGoogle Scholar
  2. 2.
    Gavin NI, Gaynes BN, Lohr KN et al (2005) Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 106:1071–1083.  https://doi.org/10.1097/01.AOG.0000183597.31630.db CrossRefGoogle Scholar
  3. 3.
    Jimenez-Solem E (2014) Exposure to antidepressants during pregnancy—prevalences and outcomes. Dan Med J 61:B4916Google Scholar
  4. 4.
    Bérard A, Chaabane S, Muanda FT et al (2016) Paroxetine use during pregnancy and the risk of cardiac defects. Br J Clin Pharmacol 82:566–567.  https://doi.org/10.1111/bcp.12979 CrossRefGoogle Scholar
  5. 5.
    Malm H, Artama M, Gissler M, Ritvanen A (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118:111–120.  https://doi.org/10.1097/AOG.0b013e318220edcc CrossRefGoogle Scholar
  6. 6.
    Huybrechts KF, Palmsten K, Avorn J et al (2014) Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370:2397–2407.  https://doi.org/10.1056/NEJMoa1312828 CrossRefGoogle Scholar
  7. 7.
    Lassen D, Ennis ZN, Damkier P (2016) First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol Toxicol 118:32–36.  https://doi.org/10.1111/bcpt.12497 CrossRefGoogle Scholar
  8. 8.
    Huybrechts KF, Bateman BT, Palmsten K et al (2015) Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313:2142–2151.  https://doi.org/10.1001/jama.2015.5605 CrossRefGoogle Scholar
  9. 9.
    Oberlander TF, Warburton W, Misri S et al (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906.  https://doi.org/10.1001/archpsyc.63.8.898 CrossRefGoogle Scholar
  10. 10.
    Levinson-Castiel R, Merlob P, Linder N et al (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160:173–176.  https://doi.org/10.1001/archpedi.160.2.173 CrossRefGoogle Scholar
  11. 11.
    Boukhris T, Sheehy O, Mottron L, Bérard A (2016) Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 170:117–124.  https://doi.org/10.1001/jamapediatrics.2015.3356 CrossRefGoogle Scholar
  12. 12.
    Grzeskowiak LE, Morrison JL, Henriksen TB et al (2016) Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG Int J Obstet Gynaecol 123:1919–1928.  https://doi.org/10.1111/1471-0528.13611 CrossRefGoogle Scholar
  13. 13.
    Kaplan YC, Keskin-Arslan E, Acar S, Sozmen K (2016) Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: a systematic review and meta-analysis. Reprod Toxicol 66:31–43.  https://doi.org/10.1016/j.reprotox.2016.09.013 CrossRefGoogle Scholar
  14. 14.
    Zoega H, Kieler H, Nørgaard M et al (2015) Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden. PLoS One.  https://doi.org/10.1371/journal.pone.0144474 Google Scholar
  15. 15.
    Charlton R, Jordan S, Pierini A et al (2015) Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG Int J Obstet Gynaecol 122:1010–1020.  https://doi.org/10.1111/1471-0528.13143 CrossRefGoogle Scholar
  16. 16.
    Hurault-Delarue C, Damase-Michel C, Finotto L et al (2016) Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database. Fundam Clin Pharmacol 30:476–482.  https://doi.org/10.1111/fcp.12209 CrossRefGoogle Scholar
  17. 17.
    Hurault-Delarue C, Chouquet C, Savy N et al (2016) How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? Pharmacoepidemiol Drug Saf 25:770–777.  https://doi.org/10.1002/pds.4000 CrossRefGoogle Scholar
  18. 18.
    Lacroix I, Hurault C, Sarramon MF et al (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65:839–846.  https://doi.org/10.1007/s00228-009-0647-2 CrossRefGoogle Scholar
  19. 19.
    WHOCC ATC classification. https://www.whocc.no/atc_ddd_index/?code=N06A&showdescription=no. Accessed 23 Mar 2017
  20. 20.
    Bérard A, Sheehy O (2014) The Quebec pregnancy cohort—prevalence of medication use during gestation and pregnancy outcomes. PLoS One.  https://doi.org/10.1371/journal.pone.0093870 Google Scholar
  21. 21.
    Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544.e1–544.e5.  https://doi.org/10.1016/j.ajog.2007.01.033
  22. 22.
    Latendresse G, Elmore C, Deneris A (2017) Selective serotonin reuptake inhibitors as first-line antidepressant therapy for perinatal depression. J Midwifery Womens Health 62:317–328.  https://doi.org/10.1111/jmwh.12607 CrossRefGoogle Scholar
  23. 23.
    Fagot J-P, Cuerq A, Samson S, Fagot-Campagna A (2016) Cohort of one million patients initiating antidepressant treatment in France: 12-month follow-up. Int J Clin Pract 70:744–751.  https://doi.org/10.1111/ijcp.12850 CrossRefGoogle Scholar
  24. 24.
    Andrade SE, Raebel MA, Brown J et al (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–194.e5.  https://doi.org/10.1016/j.ajog.2007.07.036
  25. 25.
    ANSM (2006) Modification de la rubrique grossesse du Résumé des Caractéristiques du Produit (RCP) de Deroxat® (chlorhydrate de paroxétine hémihydraté)—ANSM: Agence nationale de sécurité du médicament et des produits de santé. http://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Modification-de-la-rubrique-grossesse-du-Resume-des-Caracteristiques-du-Produit-RCP-de-Deroxat-R-chlorhydrate-de-paroxetine-hemihydrate. Accessed 20 Dec 2016
  26. 26.
    ANSM (2005) Paroxetine* et risque de malformation congénitale: points d’étape sur les résultats de l’évaluation européenne—ANSM : Agence nationale de sécurité du médicament et des produits de santé. http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Paroxetine-et-risque-de-malformation-congenitale-points-d-etape-sur-les-resultats-de-l-evaluation-europeenne. Accessed 20 Dec 2016
  27. 27.
    FDA (2006) Postmarket drug safety information for patients and providers—public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124348.htm. Accessed 24 Mar 2017
  28. 28.
    FDA (2005) Postmarket drug safety information for patients and providers—public health advisory: paroxetine. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm. Accessed 24 Mar 2017
  29. 29.
    Howard LM, Molyneaux E, Dennis C-L et al (2014) Non-psychotic mental disorders in the perinatal period. Lancet 384:1775–1788.  https://doi.org/10.1016/S0140-6736(14)61276-9 CrossRefGoogle Scholar
  30. 30.
    Coll C, de VN, da Silveira, Bassani MF DG, et al (2017) Antenatal depressive symptoms among pregnant women: evidence from a Southern Brazilian population-based cohort study. J Affect Disord 209:140–146.  https://doi.org/10.1016/j.jad.2016.11.031 CrossRefGoogle Scholar
  31. 31.
    Li Y, Long Z, Cao D, Cao F (2016) Maternal history of child maltreatment and maternal depression risk in the perinatal period: a longitudinal study. Child Abuse Negl 63:192–201.  https://doi.org/10.1016/j.chiabu.2016.12.001 CrossRefGoogle Scholar
  32. 32.
    Wong J, Motulsky A, Eguale T et al (2016) Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. JAMA 315:2230–2232.  https://doi.org/10.1001/jama.2016.3445 CrossRefGoogle Scholar
  33. 33.
    Cohen LS, Altshuler LL, Harlow BL et al (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507.  https://doi.org/10.1001/jama.295.5.499 CrossRefGoogle Scholar
  34. 34.
    Yonkers KA, Gotman N, Smith MV et al (2011) Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiol Camb Mass 22:848–854.  https://doi.org/10.1097/EDE.0b013e3182306847 Google Scholar
  35. 35.
    Hanley GE, Oberlander TF (2014) The effect of perinatal exposures on the infant: Antidepressants and depression. Best Pract Res Clin Obstet Gynaecol 28:37–48.  https://doi.org/10.1016/j.bpobgyn.2013.09.001 CrossRefGoogle Scholar
  36. 36.
    Wu J, Davis-Ajami ML (2014) Antidepressant treatment persistence in low-income, insured pregnant women. J Manag Care Spec Pharm 20:631–637.  https://doi.org/10.18553/jmcp.2014.20.6.631 Google Scholar
  37. 37.
    Lupattelli A, Spigset O, Björnsdóttir I et al (2015) Patterns and factors associated with low adherence to psychotropic medications during pregnancy–a cross-sectional, multinational web-based study. Depress Anxiety 32:426–436.  https://doi.org/10.1002/da.22352 CrossRefGoogle Scholar
  38. 38.
    INSEE (2016) Les naissances en 2015. https://www.insee.fr/fr/statistiques/2106549?sommaire=2106619. Accessed 20 Dec 2016

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Caroline Hurault-Delarue
    • 1
    Email author
  • Isabelle Lacroix
    • 1
  • Anne Bénard-Laribière
    • 2
  • Jean-Louis Montastruc
    • 1
  • Antoine Pariente
    • 2
  • Christine Damase-Michel
    • 1
  1. 1.Laboratoire de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Information sur le Médicament, INSERM/UPS UMR 1027, CIC INSERM 1436Faculté de Médecine de l’Université Paul-Sabatier et Centre Hospitalier UniversitaireToulouseFrance
  2. 2.Université Bordeaux, Inserm, CHU Bordeaux, Service de Pharmacologie Médicale, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219BordeauxFrance

Personalised recommendations